Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THULITE trial of oral BI 1815368 in centre-involved diabetic macular edema
2024-520384-14-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing BI 1815368 with Placebo (2 arms). Primary endpoint: Gain of at least 10 ETDRS letters at Week 48. Planned start Nov 2025; status: authorised.
02
Drugs
BI 1815368
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2024-520384-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520384-14-00.